Standout Papers
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes (2009)
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis (2010)
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment (2008)
- MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients (2006)
- Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms (2007)
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status (2010)
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) (2009)
- Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel (2007)
- Myelofibrosis with Myeloid Metaplasia (2000)
- Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis (2014)
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study (2011)
- The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion (2018)
- CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons (2014)
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis (2015)
- Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management (2023)
Immediate Impact
12 by Nobel laureates 14 from Science/Nature 77 standout
Citing Papers
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Acute myeloid leukaemia
2023 Standout
Works of Ayalew Tefferi being referenced
Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy
2021
Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis
2019
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Ayalew Tefferi | 37379 | 34157 | 21733 | 1.1k | 53.3k | |
| Moshe Talpaz | 22419 | 28654 | 10816 | 765 | 44.0k | |
| Andreas Hochhaus | 23691 | 29429 | 5953 | 819 | 39.2k | |
| Francis J. Giles | 15414 | 20046 | 14728 | 778 | 41.0k | |
| Srđan Verstovšek | 18322 | 18254 | 11874 | 1.1k | 29.2k | |
| Tiziano Barbui | 16252 | 17492 | 11002 | 545 | 29.6k | |
| Jörge E. Cortes | 40429 | 58990 | 23185 | 2.2k | 82.8k | |
| Guillermo Garcia‐Manero | 14343 | 29771 | 17388 | 1.5k | 42.9k | |
| Michele Baccarani | 14203 | 19737 | 4825 | 704 | 28.3k | |
| John M. Goldman | 13997 | 21809 | 5044 | 486 | 29.2k | |
| Susan O’Brien | 16969 | 20888 | 8142 | 837 | 35.7k |
All Works
Login with ORCID to disown or claim papers
Loading papers...